ArticleRheumatology international2017
Serum amyloid A as a marker of disease activity and treatment response in Takayasu arteritis.
Article in Rheumatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- The potential role of serum amyloid A as biomarker of rheumatic diseases: a systematic review and meta-analysis.Clinical and experimental medicine · 2024Pooled it
- Calprotectin and serum amyloid A for disease activity assessment in giant cell arteritis and polymyalgia rheumatica: results from a prospective single-centre cohort study.Rheumatology international · 2026Article
- Biomarkers in Primary Systemic Vasculitides: Narrative Review.International journal of molecular sciences · 2026Review
- Serum Proteomics Identified the Association of Haptoglobin and Orosomucoid 1 with Disease Activity in Takayasu Arteritis.Journal of inflammation research · 2026Article
- Advances in the pathophysiology, diagnosis and treatment of Takayasu arteritis.Nature reviews. Rheumatology · 2025Review
- A retrospective study of infantile-onset Takayasu arteritis: experience from a tertiary referral center in China.Frontiers in cardiovascular medicine · 2024Article
- Serum amyloid A-A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19.Frontiers in medicine · 2023Review
- Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis.Diagnostics (Basel, Switzerland) · 2022Review
- Tuning Monocytes and Macrophages for Personalized Therapy and Diagnostic Challenge in Rheumatoid Arthritis.Cells · 2021Review
- Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides.Current rheumatology reports · 2021Review
- Serum Amyloid A Is a Biomarker of Disease Activity and Health-Related Quality-of-Life in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Disease markers · 2020Article
- Regressed coronary ostial stenosis in a young female with Takayasu arteritis: a case report.BMC cardiovascular disorders · 2019Article
- Childhood-Onset Takayasu Arteritis (c-TA): Current and Future Drug Therapy.Paediatric drugs · 2019Review
- The C-Reactive Protein/Albumin Ratio and Complete Blood Count Parameters as Indicators of Disease Activity in Patients with Takayasu Arteritis.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Biomarkers in Vasculitides of the Nervous System.Frontiers in neurology · 2019Review
- Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker.Frontiers in immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessment of disease activity in Takayasu arteritis (TA) is challenging. We aimed to study utility of serum amyloid A (SAA) to assess disease activity and its association with SAA gene polymorphisms, if any, in our TA patients. Serum of 99 consecutive adult TA patients and 40 healthy controls were assayed for SAA. Depending on the ITAS2010 and ITAS-CRP score, patients were designated as having active disease if ITAS2010 ≥ 2 or ITAS-CRP ≥ 3 and stable disease if ITAS2010 = 0 or ITAS-CRP is ≤1. Clinical ITAS of 0 with raised inflammatory markers scoring a ITAS-CRP of 2 was considered as indeterminate for disease activity assessment. Repeat SAA levels for active group was measured after 6 months from baseline. SAA levels between active and stable disease as well as serial levels were compared. DNA of 40 patients and controls were genotyped for SAA polymorphisms (rs12218, rs2468844) and the allele frequencies were compared. At baseline, SAA levels were higher in patients as compared to controls (137.4 vs 100.8 ng/ml, p = 0.001) and higher in patients with active disease (166.4 ng/ml) than those with stable disease (98.2 ng/ml), p = 0.001. SAA decreased during follow-up in treatment responders (189.9 ng/ml at baseline vs 119.0 ng/ml at follow-up, p = 0.008); in contrast, there was no significant change among non-responders during follow-up. Allelic frequencies of SAA gene polymorphisms did not differ between cases and controls. SAA may be a reliable biomarker to assess disease activity and treatment response in TA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.